Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mannatech in NASDAQ

This article was originally published in The Tan Sheet

Executive Summary

The Coppell, Tex.-based dietary supplement marketer now is included in the new NASDAQ Global Select Market, Mannatech announces June 28. The NASDAQ Global Select Market "has the highest initial listing standards of any exchange in the world based on financial and liquidity requirements," the firm explains. Previously, Mannatech had been listed on the NASDAQ National Market. NASDAQ will implement its new three-tiered listing classification system beginning July 3. All NASDAQ-listed companies will be classified under three tiers: NASDAQ Global Select Market, NASDAQ Global Market and NASDAQ Capital Market, Mannatech explained. Additionally, Terence O'Day has been appointed as executive vice president of global operations, the firm announces in a separate, same-day release. O'Day "will be responsible for all aspects of supply chain operations including global raw materials, contract manufacturing, product warehousing and logistics, global facilities procurement, regulatory affairs, and quality assurance," the company states...

You may also be interested in...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts